Preclinical Childhood Tumor Models: Drug Efficacy Biomarker Identification and Validation
Over the past 35 years, cure rates for pediatric cancers have increased dramatically. However, it is clear that further dose intensification using cytotoxic agents or radiation therapy is not possible without enhancing morbidity and long-term effects. Consequently, novel, less genotoxic, agents are...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2015-08-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fonc.2015.00193/full |
id |
doaj-4adea9f5f06c414a9408907418bdc020 |
---|---|
record_format |
Article |
spelling |
doaj-4adea9f5f06c414a9408907418bdc0202020-11-24T20:49:05ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2015-08-01510.3389/fonc.2015.00193150307Preclinical Childhood Tumor Models: Drug Efficacy Biomarker Identification and ValidationBrian eGeier0Dias eKurmashev1Raushan T Kurmasheva2Peter J Houghton3Nationwide Children's HospitalUniversity of TexasUniversity of TexasUniversity of TexasOver the past 35 years, cure rates for pediatric cancers have increased dramatically. However, it is clear that further dose intensification using cytotoxic agents or radiation therapy is not possible without enhancing morbidity and long-term effects. Consequently, novel, less genotoxic, agents are being sought to complement existing treatments. Here we discuss preclinical human tumor xenograft models of pediatric cancers that may be used practically to identify novel agents, and ‘omics’ approaches to identifying biomarkers that may identify sensitive and resistant tumors to these agents.http://journal.frontiersin.org/Journal/10.3389/fonc.2015.00193/fullData Miningbioinformaticsxenograftschildhood cancerPreclinical PharmacologyHuman tumor xenografts; drug sensitivity; expression profiling; copy number variation; elastic net; long-intergenic non-coding RNA’s |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Brian eGeier Dias eKurmashev Raushan T Kurmasheva Peter J Houghton |
spellingShingle |
Brian eGeier Dias eKurmashev Raushan T Kurmasheva Peter J Houghton Preclinical Childhood Tumor Models: Drug Efficacy Biomarker Identification and Validation Frontiers in Oncology Data Mining bioinformatics xenografts childhood cancer Preclinical Pharmacology Human tumor xenografts; drug sensitivity; expression profiling; copy number variation; elastic net; long-intergenic non-coding RNA’s |
author_facet |
Brian eGeier Dias eKurmashev Raushan T Kurmasheva Peter J Houghton |
author_sort |
Brian eGeier |
title |
Preclinical Childhood Tumor Models: Drug Efficacy Biomarker Identification and Validation |
title_short |
Preclinical Childhood Tumor Models: Drug Efficacy Biomarker Identification and Validation |
title_full |
Preclinical Childhood Tumor Models: Drug Efficacy Biomarker Identification and Validation |
title_fullStr |
Preclinical Childhood Tumor Models: Drug Efficacy Biomarker Identification and Validation |
title_full_unstemmed |
Preclinical Childhood Tumor Models: Drug Efficacy Biomarker Identification and Validation |
title_sort |
preclinical childhood tumor models: drug efficacy biomarker identification and validation |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Oncology |
issn |
2234-943X |
publishDate |
2015-08-01 |
description |
Over the past 35 years, cure rates for pediatric cancers have increased dramatically. However, it is clear that further dose intensification using cytotoxic agents or radiation therapy is not possible without enhancing morbidity and long-term effects. Consequently, novel, less genotoxic, agents are being sought to complement existing treatments. Here we discuss preclinical human tumor xenograft models of pediatric cancers that may be used practically to identify novel agents, and ‘omics’ approaches to identifying biomarkers that may identify sensitive and resistant tumors to these agents. |
topic |
Data Mining bioinformatics xenografts childhood cancer Preclinical Pharmacology Human tumor xenografts; drug sensitivity; expression profiling; copy number variation; elastic net; long-intergenic non-coding RNA’s |
url |
http://journal.frontiersin.org/Journal/10.3389/fonc.2015.00193/full |
work_keys_str_mv |
AT brianegeier preclinicalchildhoodtumormodelsdrugefficacybiomarkeridentificationandvalidation AT diasekurmashev preclinicalchildhoodtumormodelsdrugefficacybiomarkeridentificationandvalidation AT raushantkurmasheva preclinicalchildhoodtumormodelsdrugefficacybiomarkeridentificationandvalidation AT peterjhoughton preclinicalchildhoodtumormodelsdrugefficacybiomarkeridentificationandvalidation |
_version_ |
1716806807826989056 |